Anesthesia, LocalCOOL-2NCT03956797
Long Term Safety of Cooling Anesthesia for Intravitreal Injection
A study testing Recens Cooling Anesthesia Device in people with Anesthesia, Local and Intravitreal Injection, run by Recens Medical, Inc. at 2 sites in United States.
Trial summary
The purpose of this clinical study is to evaluate the long term safety and efficacy of cooling anesthesia application to the eye as anesthesia for intravitreal injection using a novel cooling anesthesia device. Read more about this study
- Who is it for?
- Ages 18 to 110 years
- Conditions the study is for
- Anesthesia, Local, Intravitreal Injection, Macular Edema
- What is being tested?
- Recens Cooling Anesthesia Device
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 2 sitesUnited States
- Study dates
- 15 Apr 2019to 2 Apr 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 110 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men and women > 18 years old at screening visit.
- Men and women who are undergoing intravitreal injections in either one eye or both eyes with either Lucentis or Eylea as part of their normal standard of care with a 30 gauge needle.
- Subject has received a minimum of 3 intravitreal injections in the study eye prior to the study visit.
- Subject is willing and able to sign the study written informed consent form (ICF).
Who cannot join
- History of presence of scleromalacia
- Preexisting conjunctival, episcleral or scleral defects
- Less than 18 years of age
- Unable to provide informed consent
- Has received less than 3 injections in the study eye
- Active severe eye disease not controlled with artificial tears and requiring Restasis or other prescription drugs for dry eye.
Show all 11Show fewer
- History of Endophthalmitis with intravitreal injection
- History of uveitis
- History of retinal detachment in either eye
- History of vitrectomy
- Subjects who received administration of cooling anesthesia as part of the COOL-1 study will not be excluded and are eligible to participate in this study.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Retina Consultants of Houston
Houston, Texas, 77030
Sierra Eye Associates
Reno, Nevada, 89502
About this study
Official title: Long Term Evaluation of the Safety and Efficacy of Cooling Anesthesia for Local Anesthesia During Intravitreal Injection (COOL-2)
The purpose of this clinical study is to evaluate the long term safety and efficacy of cooling anesthesia application to the eye as anesthesia for intravitreal injection using a novel cooling anesthesia device.
Read the detailed description
Intravitreal injections have become the standard of care for administering medications for retinal diseases such as age related macular degeneration and diabetic macular edema.
There is considerable apprehension among patients receiving these injections, primarily revolving around adequate anesthesia during the injection. Current methods of anesthesia involve topical anesthetic drops, lidocaine gels, or subconjunctival injections of lidocaine, which suffer from either poor anesthetic effect, corneal irritation, or subconjunctival hemorrhage, as well as significant time for the onset of anesthesia.
Recens Medical has developed a novel medical device which can precisely and rapidly cool the surface of the eye This device cools to a temperature around -5 to -15 degrees Celsius, about the temperature of a cold ice cube, and thus has an excellent safety profile compared to conventional ophthalmic cryotherapy units. The value of such a device is both improved patient comfort, as well as increased efficiency and workflow for retina specialists administering intravitreal injections.
This device has been extensively tested in animal safety studies as well as pilot human studies and has not demonstrated any serious adverse effects and has shown anesthetic effects comparable to current standard of care.
The purpose of this clinical study is to evaluate the long term safety and efficacy of cooling anesthesia application to the eye as anesthesia for intravitreal injection using a novel cooling anesthesia device.
- Conditions
- Anesthesia, Local, Intravitreal Injection, Macular Edema, Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema
- Being tested
- Recens Cooling Anesthesia Device
- Keywords
- Intravitreal Injection, Anesthesia, Macular Degeneration, Diabetic Macular Edema
- Medical subject headings
- Macular Edema, Macular Degeneration, Diabetic Retinopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Recens Cooling Anesthesia DeviceDevice
Application of cooling anesthesia device prior to intravitreal injection
| Study group | Role | What they receive |
|---|---|---|
| -15 degrees Celsius for 10 seconds | Experimental | Cooling anesthesia device applied to the eye at -15 degrees Celsius for 10 seconds. Receives: Device: Recens Cooling Anesthesia Device |
| -15 degrees Celsius for 15 seconds | Experimental | Cooling anesthesia device applied to the eye at -15 degrees Celsius for 15 seconds. Receives: Device: Recens Cooling Anesthesia Device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain of Intravitreal Injection: VAS
Pain of intravitreal injection as measured by 10-point visual analog scale (VAS) (0 meaning no pain, 10 meaning the most severe pain).
Measured: Immediately after injection
Incidence of Anesthesia-Related Adverse Events
% of patients that experience cooling anesthesia device-related adverse events, as assessed by anterior segment and posterior segment examination.
Measured: 30 minutes after injection
Secondary outcomes (4)
Patient Movement During Intravitreal Injection
Physician's evaluation of the subject's movement during the intravitreal injection procedure in response to needle penetration (0 = no movement, 1 = mild movement, 2 = marked movement).
Measured: During injection
Time
Recording of the time it takes to perform intravitreal injection procedure.
Measured: Time for entire intravitreal injection procedure
Patient Anesthetic Preference
Patient response to a questionnaire asking which method of anesthesia they prefer: standard of care or the cooling anesthesia device.
Measured: 24-48 hours after injection
Pain of Intravitreal Injection (Follow-Up): VAS
Pain of intravitreal injection as measured by 10-point visual analog scale (0 meaning no pain, 10 meaning the most severe pain) during follow-up phone call.
Measured: 24-48 hours after injection
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 May 2019
- Study start15 Apr 2019
- Primary completion31 Mar 2021
- Study completion2 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Anesthesia, LocalStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- A long term safety, dose escalation study design of differing temperatures and duration to test safety and efficacy of cooling anesthesia for intravitreal injection.
- Masking
- None (open label)
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Recens Medical, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Arshad Khanani, MD, Principal investigator, Sierra Eye Associates
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03956797
- Sponsor's protocol ID
- COOL-2.0
- Acronym
- COOL-2
- Status last verified
- Aug 2022
- First submitted
- 25 Apr 2019
- Last updated
- 31 Aug 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- Undecided: Results of this study will be presented at a national meeting
Publications
Khanani AM, Patel SN, Wykoff CC, Kim GH, Kuriyan AE. Long term evaluation of the safety and efficacy of local cooling anesthesia during intravitreal injections: The COOL-2 Trial. PLoS One. 2026 Jun 10;21(6):e0349554. doi: 10.1371/journal.pone.0349554. eCollection 2026.
PubMed 42268873
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Long Term Evaluation of the Safety and Efficacy of Cooling Anesthesia for Local Anesthesia During Intravitreal Injection (COOL-2)
- ClinicalTrials.gov ID
- NCT03956797
- Acronym / sponsor ID
- COOL-2 / COOL-2.0
- Conditions
- Anesthesia, Local, Intravitreal Injection, Macular Edema, Macular Degeneration, Diabetic Retinopathy, Diabetic Macular Edema
- Keywords
- Intravitreal Injection, Anesthesia, Macular Degeneration, Diabetic Macular Edema
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Recens Medical, Inc.Industry (pharma, biotech, devices)
- Study start
- 15 Apr 2019 (actual)
- Primary completion
- 31 Mar 2021 (actual)
- Study completion
- 2 Apr 2021 (actual)
- First posted
- 21 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this clinical study is to evaluate the long term safety and efficacy of cooling anesthesia application to the eye as anesthesia for intravitreal injection using a novel cooling anesthesia device.
Detailed description
Intravitreal injections have become the standard of care for administering medications for retinal diseases such as age related macular degeneration and diabetic macular edema.
There is considerable apprehension among patients receiving these injections, primarily revolving around adequate anesthesia during the injection. Current methods of anesthesia involve topical anesthetic drops, lidocaine gels, or subconjunctival injections of lidocaine, which suffer from either poor anesthetic effect, corneal irritation, or subconjunctival hemorrhage, as well as significant time for the onset of anesthesia.
Recens Medical has developed a novel medical device which can precisely and rapidly cool the surface of the eye This device cools to a temperature around -5 to -15 degrees Celsius, about the temperature of a cold ice cube, and thus has an excellent safety profile compared to conventional ophthalmic cryotherapy units. The value of such a device is both improved patient comfort, as well as increased efficiency and workflow for retina specialists administering intravitreal injections.
This device has been extensively tested in animal safety studies as well as pilot human studies and has not demonstrated any serious adverse effects and has shown anesthetic effects comparable to current standard of care.
The purpose of this clinical study is to evaluate the long term safety and efficacy of cooling anesthesia application to the eye as anesthesia for intravitreal injection using a novel cooling anesthesia device.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- A long term safety, dose escalation study design of differing temperatures and duration to test safety and efficacy of cooling anesthesia for intravitreal injection.
| Arm | Type | Receives |
|---|---|---|
| -15 degrees Celsius for 10 seconds | Experimental | Device: Recens Cooling Anesthesia DeviceCooling anesthesia device applied to the eye at -15 degrees Celsius for 10 seconds. |
| -15 degrees Celsius for 15 seconds | Experimental | Device: Recens Cooling Anesthesia DeviceCooling anesthesia device applied to the eye at -15 degrees Celsius for 15 seconds. |
Who may qualify
- Ages
- 18 to 110 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Men and women > 18 years old at screening visit.
- Men and women who are undergoing intravitreal injections in either one eye or both eyes with either Lucentis or Eylea as part of their normal standard of care with a 30 gauge needle.
- Subject has received a minimum of 3 intravitreal injections in the study eye prior to the study visit.
- Subject is willing and able to sign the study written informed consent form (ICF).
Key exclusion criteria (11 listed)
- History of presence of scleromalacia
- Preexisting conjunctival, episcleral or scleral defects
- Less than 18 years of age
- Unable to provide informed consent
- Has received less than 3 injections in the study eye
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Recens Cooling Anesthesia DeviceApplication of cooling anesthesia device prior to intravitreal injection | Device | -15 degrees Celsius for 10 seconds, -15 degrees Celsius for 15 seconds |
Primary outcome
Pain of Intravitreal Injection: VAS
Time frame: Immediately after injection
Pain of intravitreal injection as measured by 10-point visual analog scale (VAS) (0 meaning no pain, 10 meaning the most severe pain).
Incidence of Anesthesia-Related Adverse Events
Time frame: 30 minutes after injection
% of patients that experience cooling anesthesia device-related adverse events, as assessed by anterior segment and posterior segment examination.
4 secondary outcomes
Patient Movement During Intravitreal Injection
Time frame: During injection
Time
Time frame: Time for entire intravitreal injection procedure
Patient Anesthetic Preference
Time frame: 24-48 hours after injection
Pain of Intravitreal Injection (Follow-Up): VAS
Time frame: 24-48 hours after injection
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2022.
- Derived from this study: PubMed 42268873Khanani AM, Patel SN, Wykoff CC, Kim GH, Kuriyan AE. Long term evaluation of the safety and efficacy of local cooling anesthesia during intravitreal injections: The COOL-2 Trial. PLoS One. 2026 Jun 10;21(6):e0349554. doi: 10.1371/journal.pone.0349554. eCollection 2026.
- Individual participant dataSharing planned: Undecided. Results of this study will be presented at a national meeting
Related trials for Anesthesia, Local
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Recruiting
Minimum Effective Local Anesthetic Volume for Ultrasound Guided Superior Trunk Block
Musculoskeletal Diseases or Conditions
RecruitingPhase 3
A Study of Changes to Prostate Procedures
Prostate Cancer
Not yet recruiting
Magnesium Sulphate as an Adjuvant in Combined Costoclavicular Block and Suprascapular Block Versus Interscalene Block for Ambulatory Shoulder Arthroscopy
Postoperative Pain, Shoulder Arthroscopy
Recruiting
Comparison of Spinal Anesthesia With Intrathecal Morphine Versus PENG Block With or Without Dexamethasone in Hip Arthroplasty
Arthropathy of Hip, Hip Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arshad Khanani, MD principal investigator
Sierra Eye Associates
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Recens Cooling Anesthesia Device in people with Anesthesia, Local and Intravitreal Injection, run by Recens Medical, Inc. at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain of Intravitreal Injection: VAS (time frame: Immediately after injection). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03956797, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2022.